logo
Kepler Capital Sticks to Their Hold Rating for Accor SA (0H59)

Kepler Capital Sticks to Their Hold Rating for Accor SA (0H59)

In a report released on June 25, Julien Richer from Kepler Capital maintained a Hold rating on Accor SA (0H59 – Research Report), with a price target of €42.00. The company's shares closed last Wednesday at €44.88.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Richer covers the Consumer Cyclical sector, focusing on stocks such as Accor SA, Whitbread, and DO & CO Aktiengesellschaft. According to TipRanks, Richer has an average return of 2.8% and a 50.68% success rate on recommended stocks.
Currently, the analyst consensus on Accor SA is a Strong Buy with an average price target of €52.28.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kepler Capital Reaffirms Their Buy Rating on Neste Corporation (0O46)
Kepler Capital Reaffirms Their Buy Rating on Neste Corporation (0O46)

Business Insider

time18 hours ago

  • Business Insider

Kepler Capital Reaffirms Their Buy Rating on Neste Corporation (0O46)

Kepler Capital analyst Pablo Cuadrado maintained a Buy rating on Neste Corporation on July 24 and set a price target of €13.80. The company's shares closed last Friday at €14.61. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Cuadrado is a 4-star analyst with an average return of 7.6% and a 56.55% success rate. Cuadrado covers the Industrials sector, focusing on stocks such as Bureau Veritas, Construcciones y Auxiliar de Ferrocarriles, and SGS SA. In addition to Kepler Capital , Neste Corporation also received a Buy from Goldman Sachs's Michele Della Vigna in a report issued on July 25. However, on the same day, Banco Santander downgraded Neste Corporation (LSE: 0O46) to a Hold.

Boss Energy (BQSSF) Gets a Hold from Macquarie
Boss Energy (BQSSF) Gets a Hold from Macquarie

Business Insider

time19 hours ago

  • Business Insider

Boss Energy (BQSSF) Gets a Hold from Macquarie

Macquarie analyst maintained a Hold rating on Boss Energy today and set a price target of A$4.45. The company's shares closed last Friday at $2.39. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In addition to Macquarie, Boss Energy also received a Hold from RBC Capital's Alistair Rankin in a report issued on July 17. However, today, Morgan Stanley downgraded Boss Energy (Other OTC: BQSSF) to a Sell. The company has a one-year high of $3.11 and a one-year low of $1.26. Currently, Boss Energy has an average volume of 23.73K.

Kepler Capital Maintained a Buy Rating on Genfit (GNFT)
Kepler Capital Maintained a Buy Rating on Genfit (GNFT)

Yahoo

time19 hours ago

  • Yahoo

Kepler Capital Maintained a Buy Rating on Genfit (GNFT)

Genfit S.A. (NASDAQ:GNFT) is one of the . On July 8, Justine Telliez from Kepler Capital maintained a Buy rating on Genfit S.A. (NASDAQ:GNFT) with a price target of €8.40. The rating comes after the company released its mid-year update on its liquidity contract with Credit Industriel et Commercial. The company noted that as of June 30, 2025, there were 201,000 shares in the liquidity account along with €398,484.67 in cash in liquidity. Moreover, the company also released details about its trading activity, which shows 1,412,901 shares were bought, 1,419,301 shares were sold, with the number of buy and sell trades standing at 2,673 and 1,894, respectively. A biotechnologist in a laboratory wearing a lab coat, preparing samples for a clinical trial. Genfit S.A. (NASDAQ:GNFT) is a French biopharmaceutical company that develops treatments and diagnostic tools for rare and serious liver diseases. While we acknowledge the potential of GNFT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store